WO1993003714A3 - Method for treatment of metabolic disorders - Google Patents

Method for treatment of metabolic disorders Download PDF

Info

Publication number
WO1993003714A3
WO1993003714A3 PCT/US1992/006536 US9206536W WO9303714A3 WO 1993003714 A3 WO1993003714 A3 WO 1993003714A3 US 9206536 W US9206536 W US 9206536W WO 9303714 A3 WO9303714 A3 WO 9303714A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
metabolic disorders
administering
animal
treating
Prior art date
Application number
PCT/US1992/006536
Other languages
French (fr)
Other versions
WO1993003714A2 (en
Inventor
Jerry R Colca
Scott D Larsen
Martin Durham Meglasson
Steven P Tanis
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to JP5504336A priority Critical patent/JPH06510760A/en
Priority to AU24075/92A priority patent/AU664710B2/en
Priority to EP92917697A priority patent/EP0600973A1/en
Publication of WO1993003714A2 publication Critical patent/WO1993003714A2/en
Publication of WO1993003714A3 publication Critical patent/WO1993003714A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

A method for treating or preventing non-insulin (Type II) diabetes mellitus by administering to an animal, including humans, a compound selected from Table 1 or a pharmaceutically acceptable salt thereof; and a method for treating or preventing excess adiposity or obesity by administering to an animal, including humans, a compound selected from Table 2 or a pharmaceutically acceptable salt thereof.
PCT/US1992/006536 1991-08-27 1992-08-11 Method for treatment of metabolic disorders WO1993003714A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP5504336A JPH06510760A (en) 1991-08-27 1992-08-11 Metabolic disorders and metabolic treatments
AU24075/92A AU664710B2 (en) 1991-08-27 1992-08-11 A method for treatment of metabolic disorders
EP92917697A EP0600973A1 (en) 1991-08-27 1992-08-11 A method for treatment of metabolic disorders and metabolism

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75005991A 1991-08-27 1991-08-27
US75056991A 1991-08-27 1991-08-27
US750,569 1991-08-27
US750,059 1991-08-27

Publications (2)

Publication Number Publication Date
WO1993003714A2 WO1993003714A2 (en) 1993-03-04
WO1993003714A3 true WO1993003714A3 (en) 1993-06-10

Family

ID=27115223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/006536 WO1993003714A2 (en) 1991-08-27 1992-08-11 Method for treatment of metabolic disorders

Country Status (5)

Country Link
EP (1) EP0600973A1 (en)
JP (1) JPH06510760A (en)
AU (3) AU664710B2 (en)
CA (1) CA2113817A1 (en)
WO (1) WO1993003714A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2706899A1 (en) * 1993-06-22 1994-12-30 Synthelabo Pyrrole derivatives, their preparation and their therapeutic application
EP0599697A1 (en) * 1992-11-24 1994-06-01 Synthelabo Pyrrole derivatives, their preparation and application in therapy
ATE222100T1 (en) * 1993-10-21 2002-08-15 Searle & Co AMIDINO DERIVATIVES USEFUL AS NO SYNTHASE INHIBITORS
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5935927A (en) * 1994-02-03 1999-08-10 The Picower Institute For Medical Research Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
FR2719844B1 (en) * 1994-05-10 1996-06-07 Synthelabo 5,6-dihydro-4h-thieno [3,4-c] pyrrole derivatives, their preparation and their therapeutic use.
GB9511757D0 (en) * 1995-05-19 1995-08-02 Univ Strathclyde Agents for reducing weight
US5955617A (en) * 1996-05-21 1999-09-21 Pharmacia & Upjohn Company Aminoguanidine carboxylate lactams for the treatment of non-insulin-dependent diabetes mellitus
JP2002512954A (en) * 1998-04-24 2002-05-08 マイトコー Compounds and methods for treating mitochondrial-related diseases
CN1198803C (en) * 1999-03-05 2005-04-27 第一三得利制药株式会社 Heterocyclic compounds having effect of activating nicoting acetylchloine alpha 4 beta 2 receptor
WO2001003680A2 (en) * 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
GB0019359D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel guanidines
SE0004462D0 (en) 2000-12-04 2000-12-04 Pharmacia Ab Novel method and use
AU2002221222A1 (en) * 2000-12-04 2002-06-18 Biovitrum Ab Novel method and use
GB0108631D0 (en) * 2001-04-05 2001-05-30 Melacure Therapeutics Ab Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
US7541477B2 (en) 2002-07-30 2009-06-02 Banyu Pharmaceutical Co., Ltd. Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
ITRM20020625A1 (en) * 2002-12-17 2004-06-18 Sigma Tau Ind Farmaceuti DERIVATIVES OF GUANIDINE VARIOUSLY REPLACED, THEIR USE AS MEDICATIONS WITH ANTI-DIABETIC AND / OR ANTIOBESITY ACTIVITY.
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JPWO2006061992A1 (en) * 2004-12-10 2008-06-05 味の素株式会社 Liver disease prevention / treatment composition
CA2642429A1 (en) * 2005-02-17 2006-08-24 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism
BRPI0620637A2 (en) 2005-12-22 2011-11-16 Neurochem Int Ltd use of compounds in the preparation of medicaments for the prevention or treatment of diabetic nephropathy, complication of renal disorder and dyslipidemia, reduced serum lipid and uric acid levels, and increased creatinine clearance and renal function
EP2058008B1 (en) * 2006-08-11 2013-08-21 National University Corporation Nagoya University Anti-obesity agent and use thereof
DE102007004781A1 (en) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Use of guanidinoacetic acid (salts) for the preparation of a health-promoting agent
GB0800383D0 (en) * 2008-01-10 2008-02-20 Univ Strathclyde Weight reducing compounds
KR101912494B1 (en) * 2012-10-18 2018-10-26 니신 쇼쿠힌 홀딩스 가부시키가이샤 Salty taste-enhancing agent and manufacturing method therefor, and salty taste-enhancing method
GB201300435D0 (en) * 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
DK3164123T3 (en) 2014-07-02 2020-08-03 Inflectis Bioscience Novel uses of benzylideneguanidine derivatives in the treatment of proteopathies
DE102016125414A1 (en) * 2016-12-22 2018-06-28 Bitop Ag Composition containing N-acetyldiaminobutyric acid
GB2609003A (en) * 2021-07-15 2023-01-25 Univ Nottingham Trent Compounds and pharmaceutical compositions for the treatment of metabolic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2673381B2 (en) * 1990-02-23 1997-11-05 持田製薬 株式会社 Pre-diabetes treatment agent and / or lipid lowering agent
AU7316591A (en) * 1990-02-28 1991-09-18 Upjohn Company, The Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEM. PHARM. BULL. vol. 18, no. 8, 1970, pages 1636 - 1642 FUJIHIRA,E., ET AL 'EFFECT OF LONG-TERM FEEDING OF TAURINE IN HEREDITARY HYPERGLYCEMIC OBESE MICE' *

Also Published As

Publication number Publication date
JPH06510760A (en) 1994-12-01
AU3061595A (en) 1995-11-09
AU2407592A (en) 1993-03-16
AU664710B2 (en) 1995-11-30
WO1993003714A2 (en) 1993-03-04
EP0600973A1 (en) 1994-06-15
CA2113817A1 (en) 1993-02-04
AU3061495A (en) 1995-11-09

Similar Documents

Publication Publication Date Title
WO1993003714A3 (en) Method for treatment of metabolic disorders
CA2045885A1 (en) Inhibition of mammalian muscle wasting and protein degradation by tetracyclines
AU609664B1 (en) A method of treating premature ejaculation using sertraline
HK129393A (en) Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus
CA2180535A1 (en) A method for treatment of psoriasis, by omeprazole or related compounds
CA2204616A1 (en) Ppar gamma antagonists for treating obesity
PL306590A1 (en) Substituted heterocyclic carboxylamides, method obtaining them and their application as therapeutic agents
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
WO1996015784A3 (en) 2,2-dichloroalkane carboxylic acids, process for preparing the same, medicament containing the same, and use thereof for treating insulin resistance
CA2015838A1 (en) Method of topically treating acne vulgaris
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
WO1992019211A3 (en) Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
IL102807A0 (en) Therapeutic compounds
AU1302388A (en) Method of treating anxiety with tetrahydrobenz(c,d)indole-6- carboxamides
RU94045271A (en) Use of 2-phenyl-3-aroylbenzothiophenes for terner&#39;s syndrome inhibition
GB9108629D0 (en) Heterocyclic pharmaceutical compounds,preparation and use
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
AU1173597A (en) Agent for prophylaxis and treatment of diabetic complications
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
EP0768083A3 (en) The use of sertraline to treat post myocardial infarction patients
AU1855088A (en) Treating agent for heart failure
HU905683D0 (en) The treatment of drug dependence by using sertraline
HU9203052D0 (en) Method for treatment of hypertension
GEP20032956B (en) Miticide Composition
WO1997005875A3 (en) A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWE Wipo information: entry into national phase

Ref document number: 2113817

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992917697

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992917697

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 469716

Country of ref document: US

Date of ref document: 19950606

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 1992917697

Country of ref document: EP